What is Ischemic Cardiomyopathy
Ischemic cardiomyopathy is left ventricular systolic dysfunction (ejection fraction ≤40%) occurring in the presence of significant obstructive coronary artery disease, representing the most common cause of heart failure worldwide. 1, 2
Core Definition and Pathophysiology
Ischemic cardiomyopathy results from the combination of:
- Irreversible loss of viable myocardium following acute myocardial infarction 2
- Dysfunctional but viable myocardium in the context of chronically reduced myocardial blood flow and diminished coronary reserve 2
- Progressive left ventricular remodeling following ischemic injury 1
The underlying pathophysiology involves atherosclerotic plaque buildup, thrombus formation, myocardial hypoperfusion, ischemic cell death, and subsequent adverse ventricular remodeling 1.
Diagnostic Criteria
The most prognostically powerful definition requires:
- Left ventricular ejection fraction ≤40% 3
- Significant coronary artery disease on angiography 4
- Multi-vessel disease OR single-vessel disease with documented prior myocardial infarction or revascularization 3
Critical caveat: Patients with single-vessel disease and no history of MI or revascularization should be classified as nonischemic for prognostic purposes, as this classification provides superior prognostic power 3.
Epidemiology and Risk Factors
- Most prevalent cause of heart failure in developed countries 1
- Strongly influenced by age and sex, with older individuals and males disproportionately affected 1
- Associated with ischemic heart disease, which remains the leading global cause of death 5
Prognosis and Outcomes
Despite therapeutic advances, ischemic cardiomyopathy carries substantial mortality:
- 1-year mortality: 16% 1
- 5-year mortality: approximately 40% in the USA and Europe 1
- Worse prognosis than nonischemic dilated cardiomyopathy, with ischemic etiology being an independent predictor of adverse outcomes 6, 3
- Higher in-hospital mortality in cardiogenic shock compared to nonischemic cardiomyopathy (OR 1.56,95% CI 1.26-1.93) 7
Poor prognostic indicators include: LV and RV enlargement, reduced ejection fraction, persistent S3 gallop, right-sided heart failure, elevated LV filling pressures, moderate-to-severe mitral regurgitation, pulmonary hypertension, left bundle branch block, recurrent ventricular tachycardia, renal/hepatic dysfunction, elevated BNP, persistently elevated troponin, peak oxygen consumption <10-12 mL·kg⁻¹·min⁻¹, and serum sodium <137 mmol/L 6.
Management Framework
Treatment goals focus on optimizing cardiovascular function, preventing progressive remodeling, reducing heart failure symptoms, and improving survival 1.
Therapeutic options include:
- Guideline-directed medical therapy (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists) 6, 5
- Coronary revascularization (PCI or CABG) when indicated 4, 8
- Device therapy (ICD, cardiac resynchronization therapy) 6, 5
- Mechanical circulatory support for advanced disease 1, 5
- Cardiac transplantation for end-stage disease 1
The combination of revascularization plus optimal medical therapy demonstrates superior outcomes compared to medical therapy alone, with significant improvements in LVEF (+10.7% vs +2.1%), reduced mortality (10.7% vs 23.2%), and fewer heart failure hospitalizations (17.8% vs 33.9%) at 24 months 8.